{"id":"https://openalex.org/W4397007110","doi":"https://doi.org/10.1016/j.esmoop.2024.103261","title":"240P Age at diagnosis and survival in metastatic breast cancer (MBC)","display_name":"240P Age at diagnosis and survival in metastatic breast cancer (MBC)","publication_year":2024,"publication_date":"2024-05-01","ids":{"openalex":"https://openalex.org/W4397007110","doi":"https://doi.org/10.1016/j.esmoop.2024.103261"},"language":"en","primary_location":{"id":"doi:10.1016/j.esmoop.2024.103261","doi":"https://doi.org/10.1016/j.esmoop.2024.103261","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.esmoop.2024.103261","pdf_url":"https://www.esmoopen.com/article/S2059-7029(24)01029-9/pdf","source":{"id":"https://openalex.org/S4210217024","display_name":"ESMO Open","issn_l":"2059-7029","issn":["2059-7029"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.esmoopen.com/article/S2059-7029(24)01029-9/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5051479086","display_name":"Kristen D. Brantley","orcid":"https://orcid.org/0000-0003-0084-4775","observed_orcids":["https://orcid.org/0000-0003-0084-4775"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K.D. Brantley","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011491566","display_name":"Gregory John Kirkner","orcid":"https://orcid.org/0009-0005-0386-5223","observed_orcids":["https://orcid.org/0009-0005-0386-5223"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G.J. Kirkner","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015055171","display_name":"Melissa E. Hughes","orcid":"https://orcid.org/0000-0001-6190-9101","observed_orcids":["https://orcid.org/0000-0001-6190-9101"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Hughes","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028909715","display_name":"L. Varella","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L. Varella","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5098677420","display_name":"Georgia L. Suggs","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G. Suggs","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":null,"display_name":"O. Cunningham","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"O. Cunningham","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013516632","display_name":"Sarah LeNoir Sammons","orcid":"https://orcid.org/0000-0003-2589-9422","observed_orcids":["https://orcid.org/0000-0003-2589-9422"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Sammons","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039694693","display_name":"Ann H. Partridge","orcid":"https://orcid.org/0000-0002-4722-4824","observed_orcids":["https://orcid.org/0000-0002-4722-4824"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A.H. Partridge","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022319770","display_name":"NU Lin","orcid":"https://orcid.org/0000-0003-2263-5413","observed_orcids":["https://orcid.org/0000-0003-2263-5413"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"N.U. Lin","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210117453"],"apc_list":{"value":3730,"currency":"USD","value_usd":3730},"apc_paid":{"value":3730,"currency":"USD","value_usd":3730},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.07157848,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"9","issue":null,"first_page":"103261","last_page":"103261"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10668","display_name":"Endometrial and Cervical Cancer Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2729","display_name":"Obstetrics and Gynecology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9980000257492065},{"id":"https://openalex.org/keywords/age-at-diagnosis","display_name":"age at diagnosis","score":1.0},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9929999709129333},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.7770000100135803},{"id":"https://openalex.org/keywords/luminal-a-subtype","display_name":"luminal A","score":0.7620000243186951},{"id":"https://openalex.org/keywords/luminal-b","display_name":"luminal B","score":0.9049999713897705},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.8640000224113464},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.8790000081062317},{"id":"https://openalex.org/keywords/disease-free-interval","display_name":"disease-free interval","score":0.8190000057220459},{"id":"https://openalex.org/keywords/recurrence","display_name":"recurrence","score":0.6140000224113464},{"id":"https://openalex.org/keywords/brain-metastases","display_name":"brain metastases","score":0.8889999985694885},{"id":"https://openalex.org/keywords/liver-metastases","display_name":"liver metastasis","score":0.9440000057220459},{"id":"https://openalex.org/keywords/breast-cancer-in-young-women","display_name":"young women with breast cancer","score":0.6370000243186951},{"id":"https://openalex.org/keywords/number-of-metastatic-sites","display_name":"number of metastatic sites","score":0.7870000004768372}],"concepts":[{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.683402955532074},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6697791814804077},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6006067991256714},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5184633135795593},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5179002285003662},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.366371214389801}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.esmoop.2024.103261","doi":"https://doi.org/10.1016/j.esmoop.2024.103261","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.esmoop.2024.103261","pdf_url":"https://www.esmoopen.com/article/S2059-7029(24)01029-9/pdf","source":{"id":"https://openalex.org/S4210217024","display_name":"ESMO Open","issn_l":"2059-7029","issn":["2059-7029"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.esmoop.2024.103261","doi":"https://doi.org/10.1016/j.esmoop.2024.103261","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.esmoop.2024.103261","pdf_url":"https://www.esmoopen.com/article/S2059-7029(24)01029-9/pdf","source":{"id":"https://openalex.org/S4210217024","display_name":"ESMO Open","issn_l":"2059-7029","issn":["2059-7029"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320314458","display_name":"National Comprehensive Cancer Network","ror":"https://ror.org/0465x5x63"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4397007110.pdf","grobid_xml":"https://content.openalex.org/works/W4397007110.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2894880912","https://openalex.org/W2793831362","https://openalex.org/W3018319220","https://openalex.org/W4413803662","https://openalex.org/W4399121815","https://openalex.org/W4396591055","https://openalex.org/W2624217268","https://openalex.org/W2796557635","https://openalex.org/W2162234285","https://openalex.org/W2070869572"],"abstract_inverted_index":{"The":[0],"influence":[1],"of":[2,9,34],"age":[3],"at":[4],"diagnosis":[5],"(dx)":[6],"on":[7],"prognosis":[8],"MBC":[10],"patients":[11],"remains":[12],"unclear.":[13],"While":[14],"recent":[15],"studies":[16],"report":[17],"better":[18],"overall":[19],"survival":[20],"(OS)":[21],"for":[22],"younger":[23],"women,":[24],"they":[25],"use":[26],"primary":[27],"v.":[28,37],"metastatic":[29],"tumor":[30],"subtype,":[31],"lack":[32],"differentiation":[33],"luminal":[35],"A":[36],"B":[38],"subtypes,":[39],"and/or":[40],"include":[41],"only":[42],"de":[43],"novo":[44],"patients.":[45]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2024-05-18T00:00:00"}